Condition: Embolic Stroke of Undetermined Source · Sponsor: Inha University Hospital
This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM). The main purpose is to evaluate the predictive value of an Artificial Intelligence ECG analysis tool, named SmartECG-AF. Participants will be classified into two groups based on the AI analysis: a "High Risk" group and a "Low to Intermediate Risk" (control) group. The study aims to compare the incidence rate of atrial fibrillation (AF) events over time between these two groups. Additionally, the study will analyze the relationship between the AI-predicted risk levels and the occurrence of major cardiovascular events during the follow-up period.
This description comes directly from the study's public registry record.
Yong-Soo Baek, MD, PhD · +82-32-890-2200 · existsoo@inha.ac.kr
Hyoung Seok Lee, MD · +82-32-890-3575 · hyoungseok_lee@inha.ac.kr
Always discuss trial participation with your own doctor first.
| Korea University Ansan Hospital | Ansan, South Korea | Recruiting |
| Inha University Hospital | Incheon, South Korea | Recruiting |
| Jeju National University Hospital | Jeju City, South Korea | Recruiting |
| Korea University Guro Hospital | Seoul, South Korea | Recruiting |
| Ajou University Hospital | Suwon, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07347691